Catherine Serke Williams

Array ( [id] => 15055333 [patent_doc_number] => 10457957 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-29 [patent_title] => Insecticidal proteins and methods of use [patent_app_type] => utility [patent_app_number] => 15/840073 [patent_app_country] => US [patent_app_date] => 2017-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 10 [patent_no_of_words] => 33521 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15840073 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17953496 [patent_doc_number] => 11479587 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-25 [patent_title] => Cationic intrinsically disordered antimicrobial peptides [patent_app_type] => utility [patent_app_number] => 16/462498 [patent_app_country] => US [patent_app_date] => 2017-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 17 [patent_no_of_words] => 19423 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16462498 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15083239 [patent_doc_number] => 20190336430 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-07 [patent_title] => COMPOSITIONS AND METHODS FOR BLOCKING ULTRAVIOLET RADIATION [patent_app_type] => utility [patent_app_number] => 16/349448 [patent_app_country] => US [patent_app_date] => 2017-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12884 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16349448 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12603474 [patent_doc_number] => 20180092988 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-05 [patent_title] => NANOCARRIERS HAVING SURFACE CONJUGATED PEPTIDES AND USES THEREOF FOR SUSTAINED LOCAL RELEASE OF DRUGS [patent_app_type] => utility [patent_app_number] => 15/807034 [patent_app_country] => US [patent_app_date] => 2017-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20099 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15807034 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12231971 [patent_doc_number] => 20180064834 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-08 [patent_title] => 'Targeted Enzymatic Degradation Of Quorum-Sensing Peptides' [patent_app_type] => utility [patent_app_number] => 15/802817 [patent_app_country] => US [patent_app_date] => 2017-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 8410 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15802817 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16305349 [patent_doc_number] => 10774127 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-15 [patent_title] => Peptide dual agonists of GIPR and GLP2R [patent_app_type] => utility [patent_app_number] => 16/341082 [patent_app_country] => US [patent_app_date] => 2017-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 16907 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16341082 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12621582 [patent_doc_number] => 20180099024 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-12 [patent_title] => METHODS, COMPOSITIONS, AND KITS INVOLVING ALTERATION OF THE CHAPERONE PROTEIN AXIS IN A SUBJECT [patent_app_type] => utility [patent_app_number] => 15/726224 [patent_app_country] => US [patent_app_date] => 2017-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12071 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15726224 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12157413 [patent_doc_number] => 20180028678 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-01 [patent_title] => 'SELF-ASSEMBLING COMPLEX FOR TARGETING CHEMICAL AGENTS TO CELLS' [patent_app_type] => utility [patent_app_number] => 15/703323 [patent_app_country] => US [patent_app_date] => 2017-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 11743 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15703323 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17323824 [patent_doc_number] => 11214820 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-01-04 [patent_title] => Functionally modified polypeptides and radiobiosynthesis [patent_app_type] => utility [patent_app_number] => 15/695831 [patent_app_country] => US [patent_app_date] => 2017-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 5 [patent_no_of_words] => 15117 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 170 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15695831 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15963107 [patent_doc_number] => 20200165305 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => USE OF CGRP RECEPTOR ANTAGONISTS IN NEUROPROTECTION AND NEUROLOGICAL DISORDERS [patent_app_type] => utility [patent_app_number] => 16/329596 [patent_app_country] => US [patent_app_date] => 2017-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29597 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16329596 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12219178 [patent_doc_number] => 20180057538 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-01 [patent_title] => 'POTENT AND HIGHLY SOLUBLE PEGYLATED COMPSTATIN PEPTIDES' [patent_app_type] => utility [patent_app_number] => 15/685364 [patent_app_country] => US [patent_app_date] => 2017-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 13249 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15685364 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12178673 [patent_doc_number] => 20180037609 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-08 [patent_title] => 'PHASE TRANSITION BIOPOLYMERS AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 15/679751 [patent_app_country] => US [patent_app_date] => 2017-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 41 [patent_no_of_words] => 17000 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15679751 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16428289 [patent_doc_number] => 10828350 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-11-10 [patent_title] => Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment [patent_app_type] => utility [patent_app_number] => 15/679896 [patent_app_country] => US [patent_app_date] => 2017-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 9 [patent_no_of_words] => 16984 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15679896 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13289241 [patent_doc_number] => 10155796 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-12-18 [patent_title] => Compositions and methods for inhibiting tumor cells by inhibiting the transcription factor ATF5 [patent_app_type] => utility [patent_app_number] => 15/661699 [patent_app_country] => US [patent_app_date] => 2017-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 56 [patent_no_of_words] => 15828 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15661699 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12151525 [patent_doc_number] => 20180022789 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-25 [patent_title] => 'GELATIN PARTICLES, METHOD FOR PRODUCING GELATIN PARTICLES, GELATIN-PARTICLECONTAINING CELLS, METHOD FOR PRODUCING GELATIN-PARTICLE-CONTAINING CELLS, AND CELLULAR STRUCTURE' [patent_app_type] => utility [patent_app_number] => 15/650142 [patent_app_country] => US [patent_app_date] => 2017-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9126 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15650142 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12449184 [patent_doc_number] => 09982248 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-05-29 [patent_title] => Factor IX polypeptide mutant, its uses and method for its production [patent_app_type] => utility [patent_app_number] => 15/650070 [patent_app_country] => US [patent_app_date] => 2017-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11894 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15650070 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12125091 [patent_doc_number] => 20180008677 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-11 [patent_title] => 'MODIFIED VASOACTIVE INTESTINAL PEPTIDES' [patent_app_type] => utility [patent_app_number] => 15/621320 [patent_app_country] => US [patent_app_date] => 2017-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 13706 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15621320 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14775067 [patent_doc_number] => 20190262431 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-29 [patent_title] => CBL-FAMILY INHIBITOR COMPRISING A CBL-FAMILY TKB DOMAIN BINDING PEPTIDE FOR THE PREVENTION OR TREATMENT OF DISEASES [patent_app_type] => utility [patent_app_number] => 16/307735 [patent_app_country] => US [patent_app_date] => 2017-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21274 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16307735 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14309619 [patent_doc_number] => 20190144513 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => THE CORE DOMAIN OF ANNEXINS AND USES THEREOF IN ANTIGEN DELIVERY AND VACCINATION [patent_app_type] => utility [patent_app_number] => 16/308702 [patent_app_country] => US [patent_app_date] => 2017-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10600 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16308702 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12660385 [patent_doc_number] => 20180111961 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-26 [patent_title] => Purification method for divalent cation binding proteins by anion exchange chromatography [patent_app_type] => utility [patent_app_number] => 15/615696 [patent_app_country] => US [patent_app_date] => 2017-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7286 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15615696 [rel_patent_id] =>[rel_patent_doc_number] =>)